Prospects for enhancers.

• Localización: Scientific American, ISSN 0036-8733, Vol. 301, Nº. 4, 2009, págs. 54-54
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • The article discusses a list of compounds, including ampakines, antihistimines, and phosphodiesterase (POE) inhibitors, that drugmakers plan to utilize to counter the affects of various forms of dementia, such as those resulting from Alzheimer's disease. Information on the drug class of the compound, how it works, and the drug developers are presented, which includes the U.S. pharmaceutical companies Cortex Pharmaceuticals, Helicon Therapeutics, and GlaxoSmithKine.